Business Context and Reporting Period
Kura Oncology, Inc. filed a Form 8-K Current Report on March 24, 2020. The filing discloses the entry into a material definitive agreement regarding new office space in Boston, Massachusetts.
Key Financial Metrics
This filing does not report revenue, profit, cash flow, margins, debt, or liquidity metrics. It focuses exclusively on the terms of a new lease agreement.
- Lease Commencement: April 1, 2020
- Location: Two Sea Port Lane, Boston, MA
- Space Size: Approximately 16,541 square feet
- Initial Term: 4 years and 3 months
- Extension Option: One option for 5 additional years
- Minimum Rent: Approximately $105,500 per month for the first year
- Rent Escalation: 2.0% increase per year over the Initial Term
- Additional Costs: Company responsible for share of operating expenses, taxes, utilities, and parking
Material Changes
The filing does not provide comparative financial data or material changes to prior periods. The material change is the creation of a new direct financial obligation through the lease agreement.
Outlook, Risks, and Contingencies
Management Commentary: The Company intends to use the premises for general office use. A copy of the full Lease will be filed as an exhibit to the Quarterly Report on Form 10-Q for the quarter ended March 31, 2020.
Risks and Contingencies: In the event of a default on certain obligations under the Lease, the Landlord retains the right to terminate the agreement and recover unpaid rent and expenses.
Investor Verification Checklist
- Verify the total annualized cost of the lease including estimated operating expenses and taxes.
- Confirm the impact of this new fixed cost on the Company's cash burn rate in the upcoming 10-Q.
- Review the full text of the Lease agreement when filed with the 10-Q for specific default clauses and termination rights.
- Assess whether the expansion to Boston aligns with the Company's current clinical development pipeline and staffing needs.